Syncona’s late-stage clinical companies have advanced past Phase II clinical trials and are primed with a number of near-term value drivers.
Syncona has a world-leading late-stage clinical portfolio developing products with the potential to treat patients across a range of diseases including: leukaemia, lymphoma, multiple myeloma and X-linked retinitis pigmentosa.
The Syncona team has established and built fully integrated companies with best-in-class manufacturing capabilities and world-leading management teams across Syncona’s late-stage clinical companies.
Key facts
Unless stated all financials at 30 September 2023
£245m
Value of late-stage clinical portfolio
9
Number of clinical trials
4
Portfolio company Board seats
Our late-stage clinical companies
Latest late-stage clinical company insights
Late-stage clinical company pipeline
Best ideas
Pre-clinical
Clinical
Late Clinical
BLA
